Response

Affiliations

¹ Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center (SS, SYW, PRS, JBL, KBR, JBY, SBE, ABC, CPG) and Department of Epidemiology and Public Health (SYW) and Section of General Internal Medicine, Department of Internal Medicine (PRS, JBL, CPG) and Department of Therapeutic Radiology (KBR, JBY, SBE) and Department of Surgery (ABC), Yale University School of Medicine, New Haven, CT; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (KDF).
² Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center (SS, SYW, PRS, JBL, KBR, JBY, SBE, ABC, CPG) and Department of Epidemiology and Public Health (SYW) and Section of General Internal Medicine, Department of Internal Medicine (PRS, JBL, CPG) and Department of Therapeutic Radiology (KBR, JBY, SBE) and Department of Surgery (ABC), Yale University School of Medicine, New Haven, CT; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (KDF). cary.gross@yale.edu.

Comment

Sounok Sen et al. J Natl Cancer Inst. 2014.

. 2014 Aug 11;106(9):dju198.

doi: 10.1093/jnci/dju198. Print 2014 Sep.

¹ Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center (SS, SYW, PRS, JBL, KBR, JBY, SBE, ABC, CPG) and Department of Epidemiology and Public Health (SYW) and Section of General Internal Medicine, Department of Internal Medicine (PRS, JBL, CPG) and Department of Therapeutic Radiology (KBR, JBY, SBE) and Department of Surgery (ABC), Yale University School of Medicine, New Haven, CT; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (KDF).
² Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center (SS, SYW, PRS, JBL, KBR, JBY, SBE, ABC, CPG) and Department of Epidemiology and Public Health (SYW) and Section of General Internal Medicine, Department of Internal Medicine (PRS, JBL, CPG) and Department of Therapeutic Radiology (KBR, JBY, SBE) and Department of Surgery (ABC), Yale University School of Medicine, New Haven, CT; Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD (KDF). cary.gross@yale.edu.

No abstract available

Comment on

Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation.
Shah C, Lanni TB, Saini H, Nanavati A, Wilkinson JB, Badiyan S, Vicini F. Shah C, et al. Breast Cancer Res Treat. 2013 Feb;138(1):127-35. doi: 10.1007/s10549-013-2412-6. Epub 2013 Jan 18. Breast Cancer Res Treat. 2013. PMID: 23329353

1. Shah C, Lanni TB, Saini H, et al. Cost-efficacy of acceleration partial-breast irradiation compared with whole-breast irradiation. Breast Cancer Res Treat. 2013;138(1):127–135 - PubMed
1. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys. 2012;82(2):715–723 - PubMed
1. Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26(13):2085–2092 - PubMed
1. Beckham WA, Popescu CC, Patenaude VV, et al. Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys. 2007;69(3):918–924 - PubMed
1. Smith GL, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012;307(17):1827–1837 - PMC - PubMed